Systemic gaps in antipsychotic treatment for schizophrenia demand holistic, patient-centered reform
Original framing: “[Comment] Antipsychotic medicines for schizophrenia: time to move forward” — The Lancet
The original framing omits the role of indigenous healing practices, the impact of trauma and social exclusion on mental health, and the historical marginalization of patient voices in clinical research. It also neglects the structural barriers to mental health care in low-income and marginalized communities.
Low structural omission detected in mainstream coverage.
This narrative is primarily produced by pharmaceutical companies and academic institutions with vested interests in maintaining the status quo of pharmacological treatment. It serves the interests of the biomedical model and obscures the influence of socioeconomic factors, patient autonomy, and alternative care systems. The framing reinforces a narrow view of mental health that prioritizes drug efficacy over holistic well-being.
In many cultures, mental health is understood as a communal and spiritual matter rather than an individual medical condition. This perspective challenges the dominant Western model and suggests the value of integrating diverse healing practices into mental health care systems.
The current reliance on antipsychotic medications for schizophrenia reflects a biomedical paradigm shaped by pharmaceutical interests and limited by structural inequalities.